
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Summit Therapeutics PLC (SMMT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SMMT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $35.21
1 Year Target Price $35.21
7 | Strong Buy |
3 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 102.64% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.65B USD | Price to earnings Ratio - | 1Y Target Price 35.21 |
Price to earnings Ratio - | 1Y Target Price 35.21 | ||
Volume (30-day avg) 10 | Beta -1.06 | 52 Weeks Range 11.29 - 36.91 | Updated Date 08/15/2025 |
52 Weeks Range 11.29 - 36.91 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.09 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -142.53% | Return on Equity (TTM) -328.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19355975474 | Price to Sales(TTM) 753.9 |
Enterprise Value 19355975474 | Price to Sales(TTM) 753.9 | ||
Enterprise Value to Revenue 6425.28 | Enterprise Value to EBITDA -5.32 | Shares Outstanding 742846976 | Shares Floating 116084649 |
Shares Outstanding 742846976 | Shares Floating 116084649 | ||
Percent Insiders 84.3 | Percent Institutions 13.04 |
Upturn AI SWOT
Summit Therapeutics PLC

Company Overview
History and Background
Summit Therapeutics PLC is a biopharmaceutical company focused on developing and commercializing medicines for unmet medical needs. Founded in 2003, it has undergone several strategic shifts, including focusing on novel therapies for Duchenne muscular dystrophy and later concentrating on oncology.
Core Business Areas
- Oncology: Focused on developing novel therapies for cancer. Their lead product candidates are aimed at solid tumors.
Leadership and Structure
The company is led by a board of directors and an executive management team. Specific details are available in their investor relations section, often including the CEO, CFO, and Chief Scientific Officer.
Top Products and Market Share
Key Offerings
- Ivonacap: Ivonacap is being studied for treatment of tumors. Clinical trials are ongoing. Market share data is not available as it is not yet approved. Major competitors include companies developing treatments for similar tumor types. Competition depends on the specific tumor being targeted.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive. It involves developing, manufacturing, and marketing medications. Key trends include personalized medicine, gene therapy, and increasing regulatory scrutiny.
Positioning
Summit Therapeutics is positioned as a research and development company focusing on novel cancer therapies. Their competitive advantage depends on the success of their clinical trials and the uniqueness of their drug candidates.
Total Addressable Market (TAM)
The TAM for cancer therapies is very large, in the hundreds of billions of dollars, due to the prevalence of the disease and the high cost of treatment. Summit Therapeutics is positioning to capture a portion of this TAM through successful commercialization of their products.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Dependence on clinical trial success
- Limited commercialization experience
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions
- Positive clinical trial results leading to regulatory approval
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
Competitive Landscape
Summit Therapeutics faces intense competition from larger, more established pharmaceutical companies with greater resources. Its success depends on its ability to develop and commercialize innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: Summit Therapeutics' growth has been primarily driven by its research and development activities. Historical revenue and earnings have been volatile due to the nature of the biopharmaceutical industry.
Future Projections: Future growth depends on the success of its drug candidates in clinical trials and subsequent regulatory approvals. Analyst estimates are not available in this response.
Recent Initiatives: Focus on clinical trials for Ivonacap.
Summary
Summit Therapeutics is a biopharmaceutical company focused on oncology. Its strength lies in its drug candidates. Its weakness lies in its dependence on positive clinical trial results. Investors should monitor clinical trial data and regulatory decisions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Summit Therapeutics PLC
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2015-03-05 | Co-CEO & Executive Chairman Mr. Robert W. Duggan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 159 | Website https://www.smmttx.com |
Full time employees 159 | Website https://www.smmttx.com |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.